Study analysis · Metabolism and Target Organ Damage · 2026
Semaglutide helps you lose weight fast, but 30% of the weight you drop could be precious muscle.
The weight-loss drug semaglutide cuts both fat and muscle, but it reduces dangerous belly fat more than other fat.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This study followed 47 people who took a weight loss drug and made lifestyle changes for 12 weeks. They measured how much fat and muscle they lost in different body parts. But because there was no comparison group of people who didn't take the drug, we can't say for sure the drug caused the changes—they could be from the lifestyle changes. So, we can only describe what happened, not prove the drug works.
What’s the bottom line?
This study looked at how semaglutide (a weight-loss drug) changes body shape in overweight adults. People took the drug and got lifestyle advice for 12 weeks.
How strong is this study?
This study is like a science experiment with only one group and no 'control' group to compare against. The group was small (only 47 people) and the study only lasted 12 weeks. Without a comparison group, we can't be sure the results are because of the drug. It's a weak study that gives us hints, but we need better studies to trust the findings.
75 / 100
- COI disclosure+40/40
- Data availability+35/35
- Code availabilitycode not shared
18 / 100
- Randomizationnot randomized
- Blindingnot blinded
- Control groupno control group
- Sample size (n=47)+4.2/20
- Follow-up+10/10
100 / 100
77 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 560 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
This design cannot establish causation — the findings describe an association, not a cause. No control group, no randomization, no blinding. Cannot distinguish drug effect from lifestyle intervention or natural variability.
No Conflicts
No conflicts of interest identified
No conflicts of interest identified in the provided text; authors are from academic institutions and no industry funding or affiliations were declared.
The study evaluates semaglutide, a product of Novo Nordisk, but no ties to the company were disclosed. The absence of a conflict of interest or funding statement may be due to incomplete text; further review of the full article is recommended.
Key takeaways
- 01
On average, people lost 6.77 kg (about 15 lbs).
- 02
About 70% of that was fat and 30% was muscle.
- 03
Belly fat decreased more than other fat.
- 04
The ratio of muscle to fat got better.
- 05
Losing some muscle is common with weight loss, but the improvement in muscle-to-fat ratio suggests the body composition change is still beneficial.
- 06
The preferential loss of belly fat is particularly good for health.
Surprising findings
- Despite losing muscle everywhere, the muscle-to-fat ratio increased in every body region.Common sense says losing muscle is bad, but because fat loss outpaced muscle loss, the proportion of muscle actually went up – meaning body composition improved.
- The left arm lost nearly three times as much muscle relative to baseline as the right arm (-7.61% vs. -2.49%).This huge asymmetry suggests that muscle loss isn't uniform – it hits inactive muscles hardest, even within the same person.
- Visceral fat reduction was significantly greater than subcutaneous fat reduction in relative terms (21.25% vs 16.09%).Many weight loss methods don't preferentially target visceral fat – semaglutide seems to do exactly that, which is great for metabolic health.
Practical takeaways
If you’re taking semaglutide, add resistance training – especially for your legs and non-dominant arm – to minimize muscle loss.
The study didn't test an exercise-only group, so we don't know how much resistance training helps, but the asymmetry finding strongly suggests it matters.
medium confidenceMonitor your waist circumference and body composition, not just weight – because belly fat loss is the real win.
The results are from 12 weeks only; long-term effects on body composition are unknown.
medium confidenceCombine semaglutide with a high-protein diet to protect muscle mass.
This specific study didn't control for protein intake, but muscle loss during weight loss is well-documented and protein helps.
low confidenceWhy this study matters
70% fat, 30% muscle – The good and bad of semaglutide weight loss
In 12 weeks, people lost an average of 6.77 kg. About 4.75 kg (70.2%) was fat, and 2.02 kg (29.8%) was muscle. While losing muscle sounds bad, the muscle-to-fat ratio actually improved because they lost more fat than muscle overall.
Anyone considering semaglutide should know they won't just lose fat – muscle loss is inevitable, but the trade-off might still be beneficial.
Belly fat takes the biggest hit
Visceral fat (deep belly fat) dropped by 21.25%, while subcutaneous fat (under the skin) only dropped by 16.09%. That’s a 5.16 percentage point advantage for visceral fat – the kind most linked to heart disease and diabetes.
This means semaglutide specifically targets the most dangerous fat, which could explain its metabolic benefits beyond just weight loss.
Legs lose the most muscle – your non-dominant arm suffers too
Muscle loss was greatest in the legs (left leg -0.54 kg, right leg -0.48 kg) and the non-dominant left arm lost significantly more muscle than the right arm (-7.61% vs. -2.49%). This suggests that keeping muscles active is crucial.
If you’re right-handed, your left arm might get weaker faster – a simple reason to start strength training while on the drug.
Metabolic markers improved across the board
HbA1c fell by 0.44%, liver enzymes ALT and AST dropped by 15 U/L and 8.6 U/L, uric acid decreased by 43.6 μmol/L, and total cholesterol fell by 0.3 mmol/L. All changes were statistically significant.
These improvements mean semaglutide isn't just about looks – it may reduce diabetes risk, fatty liver, and gout risk in just 12 weeks.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
This study looked at how semaglutide (a weight-loss drug) changes body shape in overweight adults. People took the drug and got lifestyle advice for 12 weeks.
Research results
On average, people lost 6.77 kg (about 15 lbs). About 70% of that was fat and 30% was muscle. Belly fat decreased more than other fat. The ratio of muscle to fat got better.
What this means - more context
Losing some muscle is common with weight loss, but the improvement in muscle-to-fat ratio suggests the body composition change is still beneficial. The preferential loss of belly fat is particularly good for health.
To explore the impact of once-weekly semaglutide-induced weight loss on regional body composition in overweight or obese adults.
A 12-week intervention with once-weekly semaglutide (escalated to 2.0 mg) and lifestyle counseling in 47 overweight/obese adults resulted in significant weight loss (mean -6.77 kg), composed of 70.2% fat mass loss and 29.8% muscle mass loss. Visceral fat reduced proportionally more than subcutaneous fat. Muscle-to-fat ratio increased across all regions. Multiple metabolic parameters improved.
Methods Used
Retrospective cohort study of 47 overweight or obese adults (BMI ≥30 or ≥27 with comorbidity). Participants received once-weekly semaglutide (0.25 mg escalated to 2.0 mg) for 12 weeks plus lifestyle intervention. Body composition was measured by dual-energy X-ray absorptiometry at baseline and week 12.
Main Finding
Semaglutide combined with lifestyle intervention significantly reduced body weight (-6.77 kg), with a greater relative reduction in visceral fat compared to subcutaneous fat, and improved muscle-to-fat ratio despite loss of lean mass. Metabolic parameters (HbA1c, ALT, AST, uric acid, total cholesterol) also improved.
Confidence Level
Moderate – small sample size (n=47), no control group, short 12-week duration, and retrospective design limit causal inference.
Study Flags
Red Flags
- •Small sample size (n=47)
- •No control or comparison group
- •Short follow-up (12 weeks)
Surprising Findings
Despite losing muscle everywhere, the muscle-to-fat ratio increased in every body region.
Common sense says losing muscle is bad, but because fat loss outpaced muscle loss, the proportion of muscle actually went up – meaning body composition improved.
Practical Takeaways
If you’re taking semaglutide, add resistance training – especially for your legs and non-dominant arm – to minimize muscle loss.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 560 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Human Cohort Study
Subject
Moderate probability
on the GRADE evidence scale
This study followed 47 people who took a weight loss drug and made lifestyle changes for 12 weeks. They measured how much fat and muscle they lost in different body parts. But because there was no comparison group of people who didn't take the drug, we can't say for sure the drug caused the changes—they could be from the lifestyle changes. So, we can only describe what happened, not prove the drug works.
The study has a COI section but no disclosure was found. A small penalty has been applied.
Strengths
- Use of DEXA for objective body composition measurement
- Standardized dosing protocol
- Consecutive enrollment to reduce selection bias
Weaknesses
- No control group (single-arm design)
- No randomization
- No blinding
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
This study looked at how semaglutide (a weight-loss drug) changes body shape in overweight adults. People took the drug and got lifestyle advice for 12 weeks.
Research results
On average, people lost 6.77 kg (about 15 lbs). About 70% of that was fat and 30% was muscle. Belly fat decreased more than other fat. The ratio of muscle to fat got better.
What this means - more context
Losing some muscle is common with weight loss, but the improvement in muscle-to-fat ratio suggests the body composition change is still beneficial. The preferential loss of belly fat is particularly good for health.
To explore the impact of once-weekly semaglutide-induced weight loss on regional body composition in overweight or obese adults.
A 12-week intervention with once-weekly semaglutide (escalated to 2.0 mg) and lifestyle counseling in 47 overweight/obese adults resulted in significant weight loss (mean -6.77 kg), composed of 70.2% fat mass loss and 29.8% muscle mass loss. Visceral fat reduced proportionally more than subcutaneous fat. Muscle-to-fat ratio increased across all regions. Multiple metabolic parameters improved.
Methods Used
Retrospective cohort study of 47 overweight or obese adults (BMI ≥30 or ≥27 with comorbidity). Participants received once-weekly semaglutide (0.25 mg escalated to 2.0 mg) for 12 weeks plus lifestyle intervention. Body composition was measured by dual-energy X-ray absorptiometry at baseline and week 12.
Main Finding
Semaglutide combined with lifestyle intervention significantly reduced body weight (-6.77 kg), with a greater relative reduction in visceral fat compared to subcutaneous fat, and improved muscle-to-fat ratio despite loss of lean mass. Metabolic parameters (HbA1c, ALT, AST, uric acid, total cholesterol) also improved.
Confidence Level
Moderate – small sample size (n=47), no control group, short 12-week duration, and retrospective design limit causal inference.
Study Flags
Red Flags
- •Small sample size (n=47)
- •No control or comparison group
- •Short follow-up (12 weeks)
Surprising Findings
Despite losing muscle everywhere, the muscle-to-fat ratio increased in every body region.
Common sense says losing muscle is bad, but because fat loss outpaced muscle loss, the proportion of muscle actually went up – meaning body composition improved.
Practical Takeaways
If you’re taking semaglutide, add resistance training – especially for your legs and non-dominant arm – to minimize muscle loss.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 560 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Human Cohort Study
Subject
Moderate probability
on the GRADE evidence scale
This study followed 47 people who took a weight loss drug and made lifestyle changes for 12 weeks. They measured how much fat and muscle they lost in different body parts. But because there was no comparison group of people who didn't take the drug, we can't say for sure the drug caused the changes—they could be from the lifestyle changes. So, we can only describe what happened, not prove the drug works.
The study has a COI section but no disclosure was found. A small penalty has been applied.
Strengths
- Use of DEXA for objective body composition measurement
- Standardized dosing protocol
- Consecutive enrollment to reduce selection bias
Weaknesses
- No control group (single-arm design)
- No randomization
- No blinding
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
This study is like a science experiment with only one group and no 'control' group to compare against. The group was small (only 47 people) and the study only lasted 12 weeks. Without a comparison group, we can't be sure the results are because of the drug. It's a weak study that gives us hints, but we need better studies to trust the findings.
75 / 100
- COI disclosure+40/40
- Data availability+35/35
- Code availabilitycode not shared
18 / 100
- Randomizationnot randomized
- Blindingnot blinded
- Control groupno control group
- Sample size (n=47)+4.2/20
- Follow-up+10/10
100 / 100
77 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 560 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
This design cannot establish causation — the findings describe an association, not a cause. No control group, no randomization, no blinding. Cannot distinguish drug effect from lifestyle intervention or natural variability.
No Conflicts
No conflicts of interest identified
No conflicts of interest identified in the provided text; authors are from academic institutions and no industry funding or affiliations were declared.
The study evaluates semaglutide, a product of Novo Nordisk, but no ties to the company were disclosed. The absence of a conflict of interest or funding statement may be due to incomplete text; further review of the full article is recommended.
Standing
Who’s using this study?
The videos and claims on this site that lean on this study, and the researchers who wrote it.
1 video from Thomas DeLauer cite this study, drawing 1 claim from it.
- Conflicting evidence
Evidence points in both directions — no clear conclusion yet.
Evidence
Authored by
6 researchersIf this is your work, this is how we attribute it on Fit Body Science. Yishan Ma is listed as the lead author.